CompletedPhase 2NCT02430077
Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients
Studying OBSOLETE: Laminopathy type Decaudain-Vigouroux
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Abhimanyu Garg
- Principal Investigator
- Abhimanyu Garg, MDUniversity of Texas Southwestern Medical Center
- Intervention
- Obeticholic Acid(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2016 – 2022
Study locations (2)
- UT Southwestern Medical Center 5323 Harry Hines Blvd, Dallas, Texas, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02430077 on ClinicalTrials.govOther trials for OBSOLETE: Laminopathy type Decaudain-Vigouroux
Additional recruiting or active studies for the same condition.
See all trials for OBSOLETE: Laminopathy type Decaudain-Vigouroux →